Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses

Gordon, Stephen ORCID: https://orcid.org/0000-0001-6576-1116, Malamba, R., Mthunthama, N., Jarman, E. R., Jambo, Kondwani C., Jere, K., Zijlstra, E. E., Molyneux, Malcolm E, Dennis, J. and French, Neil (2008) 'Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses'. Vaccine, Vol 26, Issue 42, pp. 5400-5406.

Preview

Text SB_Gordon_Inhaled_delivery_of_23-valent.pdf - Other Available under License Creative Commons Attribution. Download (681kB)

Abstract

We compared the effect of intramuscular vs. inhaled 23-valent pneumococcal capsular polysaccharide vaccine (23-PPV) oil pulmonary mucosal immunoglobulin levels. Bronchoalveolar lavage (BAL) and serum were collected from 33 adults before and I month after injected (n = 16) or inhaled (it = 17) 23-PPV. Levels of pneumococcal capsule-specific IgG and IgA to types 1, 9V and 14 were measured in each sample. Injected 23-PPV produced a significant increase in types 1, 9V and 14 capsule-specific IgG and type I IgA in both serum and BAL (type I geometric mean BAL IgG 9.8 ng/ml post-vaccine vs. 5 ng/ml pre-vaccine, p = 0.01; type 9V geo mean 5.6 ng/ml vs. 2.7 ng/ml, p = 0.001; type 14 geo mean 23.6 ng/ml vs. 6.2 ng/ml, p = 0.02). Inhaled vaccine produced no response in either BAL or serum. (C) 2008 Elsevier Ltd. All rights reserved.

Item Type:	Article
Additional Information:	PubMed Sponsored document from Vaccine
Uncontrolled Keywords:	inhaled pneumococcal vaccine lung pneumonia streptococcus pneumoniae immunoglobulin mucosa bronchoalveolar lavage polysaccharide human alveolar macrophages infected malawian adults placebo-controlled trial streptococcus-pneumoniae conjugate vaccine inhalative vaccination double-blind disease efficacy antibody
Subjects:	QW Microbiology and Immunology > Immune Responses > QW 700 Infection. Mechanisms of infection and resistance. QW Microbiology and Immunology > Immunotherapy and Hypersensitivity > QW 805 Vaccines. Antitoxins. Toxoids QW Microbiology and Immunology > Immunotherapy and Hypersensitivity > QW 806 Vaccination WA Public Health > Preventive Medicine > WA 108 Preventive health services. Preventive medicine. Travel Medicine. WA Public Health > Preventive Medicine > WA 110 Prevention and control of communicable diseases. Transmission of infectious diseases WA Public Health > Preventive Medicine > WA 115 Immunization WC Communicable Diseases > Infection. Bacterial Infections > Bacterial Infections > WC 202 Pneumonia (General or not elsewhere classified) WC Communicable Diseases > Infection. Bacterial Infections > Bacterial Infections > WC 204 Pneumococcal pneumonia. Staphylococcal pneumonia WC Communicable Diseases > Infection. Bacterial Infections > Bacterial Infections > WC 217 Pneumococcal infections WC Communicable Diseases > Infection. Bacterial Infections > Bacterial Infections > WC 240 Bacteremia. Sepsis. Toxemias WC Communicable Diseases > Infection. Bacterial Infections > Bacterial Infections > WC 250 Staphylococcal infections
Faculty: Department:	Groups (2002 - 2012) > Clinical Group
Digital Object Identifer (DOI):	https://doi.org/10.1016/j.vaccine.2008.07.082
Depositing User:	Users 43 not found.
Date Deposited:	25 Aug 2010 14:35
Last Modified:	17 Aug 2022 08:56
URI:	https://archive.lstmed.ac.uk/id/eprint/795

Statistics

View details

Actions (login required)

Edit Item